The global hyperlipidemia drugs market size is projected expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the presence of novel drug classes with improved efficacy & safety and introduction of new guidelines that redefined at-risk patient groups.
Hyperlipidemia is a term for a variety of acquired or inherited diseases associated with high amount of lipids such as fats, cholesterol, and triglycerides in the bloodstream. Triglycerides and cholesterol are the two main types of lipids present in the blood. Triglycerides are formed when your body retains excess calories that it does not require for energy. Triglycerides are raised by a diet rich in refined sugar, fructose, and alcohol. Because every cell in your body requires cholesterol, it is generated naturally in your liver. Cholesterol, like triglycerides, is present in fatty meals like eggs, red meat, and cheese. High cholesterol is a term used to describe hyperlipidemia.
Although high cholesterol can be passed down the generations, it is more commonly the result of poor lifestyle choices. As hyperlipidemia has no symptoms, a blood test called a lipid panel, or a lipid profile is the only method to identify it. Cholesterol levels are determined by this test. The doctor will take a sample of blood and send it to a lab for testing. Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides are all included in the report. LDL and HDL are the two types of cholesterol. The terms bad and good cholesterol are commonly used to describe them. LDL (bad) cholesterol builds up in the walls of your arteries, hardening and narrowing them. HDL (good) cholesterol removes extra bad cholesterol from the arteries and transports it to the liver.
Hyperlipidemia is a condition in which your blood has too much LDL cholesterol and not enough HDL cholesterol to remove it. Eating foods high in saturated and trans fats, eating animal protein such as meat and dairy, not getting enough exercise, not eating enough healthy fats, obesity, a large waist circumference, smoking, and excessive alcohol consumption are all lifestyle choices that increases risk for high cholesterol. Some persons with specific health problems, such as renal illness, diabetes, polycystic ovarian syndrome, pregnancy, underactive thyroid, and hereditary disorders, have abnormal cholesterol levels.
The key to treating hyperlipidemia at home is to make lifestyle modifications. Even if you have hereditary hyperlipidemia (familial mixed hyperlipidemia), lifestyle modifications are still necessary for therapy. These modifications may be sufficient to lower your risk of problems such as heart disease and stroke. If a patient is currently taking medicines to reduce cholesterol, making lifestyle modifications might help them work even better. Diet and lifestyle modifications may be sufficient for some people to lower their cholesterol levels to a healthy level. Others may require additional assistance. Statins are drugs that stop your liver from producing cholesterol. They are a popular choice for lowering cholesterol levels in the blood. A novel type of medication prevents cholesterol from being absorbed into your body through your gut. They are known as cholesterol absorption inhibitors, and they operate in tandem with statins. The medication ezetimibe is an example (Zetia). Another form of medicine, resins, deceive the body into burning cholesterol. They attach to bile, a digestive acid, preventing it from doing its purpose. The liver must produce more bile, which necessitates the use of cholesterol. As a result, there is less cholesterol in the circulation. There might be additional new therapy alternatives to think about. It is advisable to speak with your doctor about this. Hyperlipidemia is generally a chronic condition that necessitates the use of statin medications to keep blood lipid levels under control.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing incidence of lifestyle related disorders such as hypertension, obesity, cardiovascular diseases as a result of sedentary lifestyle is major factor driving the market growth.
- Growing geriatric population around the world, geriatric population is more prone high cholesterol and cardiovascular disorders is projected to fuel the market growth in the coming years.
- Introduction of new drug classes with enhanced endothelial function and stable atherosclerotic plaques is anticipated to drive the market growth during the forecast period.
- Lower costs for PCSK9 inhibitors like Repatha and Praluent are expected to replace numerous costly treatments this in turn is expected to boost the market growth in the coming years.
- Side effects associated with hyperlipidemia drugs are expected to restrict the market growth during the forecast period.
- Extensive R&D activities in the field of biomedical sciences, technological advancements, improved healthcare infrastructure, and development of novel hyperlipidemia drugs with improved efficacy are estimated to offer significant opportunities for the market players.
Scope of the Report
The report on the global hyperlipidemia drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Hyperlipidemia Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, and Miscellaneous Antihyperlipidemic Agents [Omega-3 Fatty Acids, Nicotinic Acids, Lomitapide, Mipomersen, and Bempedoic Acid]) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Amgen Inc.; AstraZeneca PLC; Daiichi Sankyo Company Limited; Eli Lilly and Company; Esperion Therapeutics Inc.; GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc); Immuron Limited; Ionis Pharmaceuticals Inc.; Merck & Co. Inc.; Pfizer Inc.; and Sanofi S.A. |
Market Segment Insights
PCSK9 inhibitors segment is expected to account for a key share
Based on drug class, the hyperlipidemia drugs market is segmented into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination, and miscellaneous antihyperlipidemic agents. Miscellaneous antihyperlipidemic segment is further sub segmented into omega-3 fatty acids, nicotinic acids, lomitapide, mipomersen, and bempedoic acid. The PCSK9 inhibitors segment is expected to account for a key share of the market during the forecast period owing to its improved efficacy, lower cost, and safety profile. Introduction of more effective treatments such as PCSK9 inhibitors and bempedoic acid, the market for statins is expected to drop throughout the forecast period. For the treatment of homozygous FH patients, PCSK9 inhibitors are likely to substitute existing costly treatments such as lomitapide and mipomersen.
On the other hand, the Miscellaneous antihyperlipidemic segment is anticipated to expand at a rapid pace during the forecast period owing to its improved safety and performance characteristics of pipeline drugs and increased acceptance among end users. Furthermore, this drug class's improved efficacy compared to statins, as well as its efficacy to lower the risk of CVD in ongoing clinical trials, are expected to drive the segment growth.
North America and Europe is anticipated to dominate the market
On the basis of regions, the hyperlipidemia drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America and Europe is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to increasing prevalence of hypercholesterolemia, with higher levels of lipoproteins and the rising baby boomer generation.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to highly established health care infrastructure and a higher acceptance rate of technologically sophisticated treatment goods. Furthermore, the aging population and increased awareness of heart disease are two factors driving the hyperlipidemia drug market. However, due to the non-availability of major revenue-generating medicines like bempedoic acid, Japan's hyperlipidemia market has fewer growth potential.
Segments
Segments Covered in the Report
The global hyperlipidemia drugs market has been segmented on the basis of
Drug Class
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
- Combination
- Miscellaneous Antihyperlipidemic Agents
- Omega-3 Fatty Acids
- Nicotinic Acids
- Lomitapide
- Mipomersen
- Bempedoic Acid
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Amgen Inc.
- AstraZeneca PLC
- Daiichi Sankyo Company Limited
- Eli Lilly
- Company
- Esperion Therapeutics Inc.
- GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
- Immuron Limited
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi S.A
Competitive Landscape
Key players competing in the hyperlipidemia drugs market are Amgen Inc.; AstraZeneca PLC; Daiichi Sankyo Company Limited; Eli Lilly and Company; Esperion Therapeutics Inc.; GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc); Immuron Limited; Ionis Pharmaceuticals Inc.; Merck & Co. Inc.; Pfizer Inc.; and Sanofi S.A.
Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
